MMP2 and inflammatory bowel disease: In conclusion, similar to infliximab treatment in CD patients, which reduces the serum expression levels of MMP-1, MMP-2, and MMP-3 [47, 48], RK-33 treatment has the potential of generating a comparable result by targeting DDX3 and lowering the expression levels in and their inflammatory contributions to IBD pathogenesis.